Nulibry is owned by Sentynl Theraps Inc.
Nulibry contains Fosdenopterin Hydrobromide.
Nulibry has a total of 1 drug patent out of which 0 drug patents have expired.
Nulibry was authorised for market use on 26 February, 2021.
Nulibry is available in powder;intravenous dosage forms.
Nulibry can be used as method of treating molybdenum cofactor deficiency type a.
Drug patent challenges can be filed against Nulibry from February, 2025.
The generics of Nulibry are possible to be released after 26 February, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7504095||SENTYNL THERAPS INC||Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency|| |
(1 year, 11 months from now)
|Orphan Drug Exclusivity (ODE)||Feb 26, 2028|
|New Chemical Entity Exclusivity (NCE)||Feb 26, 2026|
NCE-1 date: February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic